Ionis Pharmaceuticals/$IONS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Ticker
$IONS
Sector
Primary listing
Employees
1,069
Headquarters
Website
IONS Metrics
BasicAdvanced
$11B
-
-$1.61
0.33
-
Price and volume
Market cap
$11B
Beta
0.33
52-week high
$76.78
52-week low
$23.95
Average daily volume
2.2M
Financial strength
Current ratio
2.788
Quick ratio
2.51
Long term debt to equity
227.158
Total debt to equity
333.266
Interest coverage (TTM)
-3.07%
Profitability
EBITDA (TTM)
-266.799
Gross margin (TTM)
7.54%
Net profit margin (TTM)
-26.48%
Operating margin (TTM)
-28.79%
Effective tax rate (TTM)
0.92%
Revenue per employee (TTM)
$900,000
Management effectiveness
Return on assets (TTM)
-5.68%
Return on equity (TTM)
-40.04%
Valuation
Price to revenue (TTM)
11.427
Price to book
18.13
Price to tangible book (TTM)
18.13
Price to free cash flow (TTM)
-35.704
Free cash flow yield (TTM)
-2.80%
Free cash flow per share (TTM)
-1.948
Growth
Revenue change (TTM)
20.41%
Earnings per share change (TTM)
-34.39%
3-year revenue growth (CAGR)
3.35%
10-year revenue growth (CAGR)
11.80%
3-year earnings per share growth (CAGR)
214.81%
10-year earnings per share growth (CAGR)
29.74%
What the Analysts think about IONS
Analyst ratings (Buy, Hold, Sell) for Ionis Pharmaceuticals stock.
Bulls say / Bears say
FDA approved Dawnzera (donidalorsen) for hereditary angioedema, providing Ionis with its second wholly-owned commercial product and broadening its revenue base beyond royalties
Market analysts project peak annual sales of $509 million by 2032 for Dawnzera, underscoring strong long-term revenue potential from Ionis’ HAE franchise
The patent infringement lawsuit and associated clinical data boosted peak sales expectations for Tryngolza to roughly $2.5 billion annually, highlighting the significant commercial promise of Ionis’ wholly-owned antisense therapies
FDA declined approval of a higher‐dose Spinraza, potentially capping future royalty growth from Ionis’ foundational SMA asset amid competitive pressures
Dawnzera’s U.S. list price of $57,462 per dose may limit insurer coverage and patient adoption, posing a risk to the projected sales ramp for Ionis’ second independent launch
Arrowhead’s countersuit challenging Ionis’ mRNA patent for its FCS treatment threatens Tryngolza exclusivity and could expose Ionis to damages or royalty losses if the patent is invalidated
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
IONS Financial Performance
Revenues and expenses
IONS Earnings Performance
Company profitability
IONS News
AllArticlesVideos
Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug
Benzinga1 day ago
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
Business Wire4 days ago
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
Business Wire6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ionis Pharmaceuticals stock?
Ionis Pharmaceuticals (IONS) has a market cap of $11B as of November 12, 2025.
What is the P/E ratio for Ionis Pharmaceuticals stock?
The price to earnings (P/E) ratio for Ionis Pharmaceuticals (IONS) stock is 0 as of November 12, 2025.
Does Ionis Pharmaceuticals stock pay dividends?
No, Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders as of November 12, 2025.
When is the next Ionis Pharmaceuticals dividend payment date?
Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders.
What is the beta indicator for Ionis Pharmaceuticals?
Ionis Pharmaceuticals (IONS) has a beta rating of 0.33. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.